Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like Multiple Myeloma Research Foundation (MMRF) Announces $15 Million Investment In Immunotherapy Initiative June 28, 2017 AstraZeneca PLC Jumps Deeper Into mRNA Drugs With Ethris Deal August 20, 2017 Novartis AG Pushes A NASH Combo Into Late-Stage Development With A Little Help From Its Friend Allergan April 17, 2017
Multiple Myeloma Research Foundation (MMRF) Announces $15 Million Investment In Immunotherapy Initiative June 28, 2017
Novartis AG Pushes A NASH Combo Into Late-Stage Development With A Little Help From Its Friend Allergan April 17, 2017
